Meshima and Prostate Cancer: Preclinical Evidence

Meshima & Cancer

2 high-impact journal studies

In athymic nude mice bearing advanced prostate cancer xenografts, Phellinus linteus injection both prevented new tumor formation and caused existing tumors to regress through caspase-mediated apoptosis.

Tsuji et al., PLoS One, 2010

AR+/AR-

two prostate cancer subtypes activate entirely different apoptotic pathways when treated with PL (Zhu 2007)

doxorubicin

PL combination enhanced chemotherapy-induced cell death vs. doxorubicin alone (Tsuji 2010)

caspase-8 + ER

two simultaneous death signals activated in hormone-sensitive prostate cancer cells (Zhu 2007)

Tsuji et al., PLoS One, 2010

View as image ↗

Two prostate cancer studies of Phellinus linteus have been published in high-impact journals: one in the British Journal of Cancer (2007) and one in PLoS ONE (2010). Together they make up essentially the entire direct evidence base for meshima's effects on prostate cancer cells. They are specific, mechanistic, and unusually candid about what they found: the mushroom extract works differently depending on the cancer's androgen receptor status, and in a mouse model, it caused actual tumor regression.

The 2007 study found something clinically meaningful: the apoptotic pathway that Phellinus linteus activates depends on whether the prostate cancer is hormone-driven or hormone-independent. These are not interchangeable cancer types. They behave differently clinically, respond differently to treatment, and, according to this research, respond differently to PL. The 2010 study found that in mice bearing advanced prostate cancer xenografts, PL injection both prevented new tumor formation and caused existing tumors to shrink through caspase-mediated cell death.

This article covers both studies in detail, the hispolon mechanism that extends the picture, and what the evidence does and doesn't support. For the foundational introduction to meshima, see What Is Meshima Mushroom. For the broader cancer apoptosis mechanism, see Meshima and Cancer Cell Apoptosis.

Why Androgen Receptor Status Defines the Cancer Type

Prostate cancer is not a single disease. It exists on a spectrum defined partly by whether the tumor's cells depend on male hormones (androgens) to grow, which is determined by whether they express the androgen receptor (AR).

Approximately 80% of newly diagnosed prostate cancers are androgen receptor positive. These cancers grow in response to testosterone and dihydrotestosterone binding to the AR. They are the reason androgen deprivation therapy (reducing testosterone production or blocking AR) is a core treatment for advanced prostate cancer. Cells that express AR are often called "hormone-sensitive" or "hormone-driven."

Castration-resistant prostate cancer develops when cancer cells adapt to survive and grow without hormonal signaling. They may lose AR expression entirely, mutate it so it activates without androgens, or find alternative growth pathways. These cells are called "castration-resistant" or AR-negative (AR-). They are harder to treat: they no longer respond to hormone therapy, and they tend to be more aggressive.

The distinction matters for understanding Phellinus linteus research because the 2007 Zhu study specifically tested both cell types and found that PL's apoptotic mechanism depends on which type you're treating.

The Zhu 2007 Study: Two Cancer Types, Two Pathways

Zhu et al. (2007) published their findings in the British Journal of Cancer, a peer-reviewed journal with a high bar for cancer research.^[1] They tested Phellinus linteus extract on two established prostate cancer cell lines: LNCaP cells, which are androgen receptor positive and hormone-sensitive, and PC3 cells, which are androgen receptor negative and typically treated as a model for castration-resistant disease.

In LNCaP cells (AR+), Phellinus linteus activated two distinct apoptotic mechanisms simultaneously.

The first was the caspase-8/BID pathway. Caspase-8 is an initiator caspase in the extrinsic apoptosis pathway: it's activated by death receptor signals at the cell surface and can directly trigger cell death. It also cleaves a protein called BID, which then activates the intrinsic (mitochondrial) pathway as a second signal. A compound that activates caspase-8/BID is recruiting both the extrinsic and intrinsic death pathways at once.

The second mechanism was endoplasmic reticulum (ER) stress signaling. The endoplasmic reticulum is the cellular factory that folds proteins. When it's overwhelmed or damaged, it activates a stress response called the unfolded protein response (UPR). If the stress is severe enough, the UPR triggers apoptosis. PL appears to stress the ER in LNCaP cells in a way that the cell cannot recover from. ER stress-mediated apoptosis is a distinct, third route to cell death that operates independently of both the extrinsic and intrinsic caspase pathways.

In PC3 cells (AR-), the response was different. Phellinus linteus still activated apoptosis, but through a more limited signal: primarily through caspase-2, which acts downstream of androgen receptor signaling. When the AR pathway is absent (as it is in PC3 cells), PL's pathway is constrained. The apoptotic response was described as moderate rather than complete. The absence of the androgen receptor appears to reduce the effectiveness of PL's principal apoptosis route in prostate cancer cells.

The clinical implication: hormone-sensitive (AR+) prostate cancers may be more susceptible to Phellinus linteus's apoptotic effects than castration-resistant (AR-) prostate cancers, based on this cell culture data. This is a nuance that no consumer content on meshima has addressed.

The Tsuji 2010 Study: From Cell Culture to Living Tissue

Animal models are an essential step between cell culture and human trials. Tsuji et al. (2010) published their results in PLoS ONE and used an athymic nude mouse model, the standard preclinical platform for testing anti-tumor compounds.^[2]

Athymic nude mice lack a functional T-cell immune system, which allows human cancer cells to grow in them without being rejected by immune surveillance. By implanting human prostate cancer cells into these mice and then treating with PL extract, the researchers could test whether the anti-tumor effects seen in cell culture translate to a living organism with intact vascular and metabolic systems.

Two distinct outcomes were observed. First, PL injection significantly reduced the formation of new tumors in mice that had been implanted with cancer cells but had not yet developed tumors. This tumor prevention effect is distinct from tumor treatment: it suggests PL may interfere with the early stages of tumor establishment, not just the growth of established tumors.

Second, in mice that had already developed prostate cancer tumors, PL injection caused the tumors to regress. The mechanism was confirmed to be apoptosis: histological analysis of tumor tissue showed caspase activation and the cellular fragmentation pattern characteristic of programmed cell death. Tumors were not just slowing in growth; they were actively losing cells.

The third finding was chemosensitization. When PL was combined with doxorubicin (a standard chemotherapy drug), cancer cell death was greater than with doxorubicin alone. PL appeared to make the cancer cells more susceptible to chemotherapy-induced death, an effect with potential relevance to adjuvant treatment strategies.

Hispolon: A Hormone-Independent Mechanism

The Zhu 2007 and Tsuji 2010 studies focus on the whole extract. Two additional studies on hispolon, a polyphenol compound from Phellinus linteus, add hormone-independent pathways that may be relevant to prostate cancer regardless of AR status.

Lu et al. (2009) found hispolon inhibited cancer cell proliferation through the MDM2/ERK1/2 pathway in breast and bladder cancer cells.^[3] MDM2 is a protein that normally suppresses p53, the tumor suppressor that triggers apoptosis in response to cellular damage. MDM2 overexpression is common in prostate cancer and is associated with more aggressive disease. Hispolon's activity through the MDM2 pathway gives it relevance to prostate cancer cells where p53 is functionally suppressed by MDM2, a common finding in castration-resistant disease.

Kim et al. (2016) found hispolon upregulated death receptors DR4 and DR5 on cancer cell surfaces, sensitizing multiple cancer cell lines to TRAIL-mediated killing.^[4] This TRAIL sensitization mechanism operates through the extrinsic pathway and is independent of androgen receptor status. It suggests that hispolon may maintain anti-cancer activity even in AR-negative prostate cancer cells, where the Zhu 2007 data suggested the whole-extract AR-dependent pathway is less effective.

The Evidence in Context

A 2010 review by Sliva placed Phellinus linteus among the most studied medicinal mushrooms for anti-tumor activity, noting 40 years of research across multiple cancer types.^[5] For prostate cancer specifically, the evidence base is small but mechanistically specific: two published studies in credible journals, both providing molecular-level data.

What those studies don't show is equally important.

Neither Zhu 2007 nor Tsuji 2010 was designed to test clinical efficacy or safety in humans. Cell culture studies use concentrations that are not achievable from oral supplementation without knowing the pharmacokinetics (absorption, distribution, and metabolism of the active compounds in a living human). Athymic nude mice lack normal immune function and don't replicate the full complexity of human prostate cancer, which is embedded in a functioning immune microenvironment, stroma, and vasculature.

The doxorubicin sensitization finding from Tsuji 2010 is a preclinical signal worth noting, but it does not mean that PL is safe or effective to combine with doxorubicin in human patients. Drug interactions in a living human are far more complex than in a mouse xenograft.

No randomized controlled trial has tested Phellinus linteus in human prostate cancer patients. The mechanistic evidence is specific and the journal pedigree is high; the clinical translation gap is substantial. For context on how meshima's anti-tumor mechanisms relate to its effects on blood vessel formation, see Meshima and Anti-Angiogenesis. For how it compares to mushrooms with clinical cancer trial data, see How Turkey Tail Enhances the Immune System's Anti-Cancer Response. For what may happen after a prostate tumor establishes and begins spreading, see Meshima and Cancer Metastasis.

The Bottom Line

Phellinus linteus's prostate cancer evidence consists of two studies published in high-impact journals: Zhu et al. (2007, British Journal of Cancer), which found different apoptotic pathways activated depending on androgen receptor status, and Tsuji et al. (2010, PLoS ONE), which found tumor regression in a mouse xenograft model and chemosensitization to doxorubicin. Hispolon, a PL polyphenol, provides AR-independent mechanisms via MDM2/ERK1/2 and TRAIL sensitization. No human trials exist.

Frequently Asked Questions

Does Meshima mushroom help prostate cancer?

Phellinus linteus has shown anti-prostate-cancer activity in two published laboratory and animal studies. Zhu et al. (2007) found it activated apoptosis in prostate cancer cells, with the specific pathway depending on whether the cancer was hormone-driven or hormone-independent. Tsuji et al. (2010) found tumor regression in mice bearing advanced prostate cancer xenografts. No human clinical trial has tested Phellinus linteus in prostate cancer patients, so it is not possible to say whether it "helps" human prostate cancer based on current evidence.

What does Phellinus linteus do to prostate cancer cells?

In laboratory studies, Phellinus linteus activates apoptosis (programmed cell death) in prostate cancer cells through pathways that depend on the cancer type. In hormone-driven (androgen receptor positive) prostate cancer cells, it activates caspase-8/BID and endoplasmic reticulum stress signaling simultaneously. In castration-resistant (AR negative) cells, it activates a less complete apoptotic pathway via caspase-2. In mice bearing advanced prostate cancer, intratumoral injection caused tumor regression. Hispolon, a PL polyphenol, additionally sensitizes cancer cells to TRAIL-mediated immune killing by upregulating death receptors DR4 and DR5.

Is there research on Meshima and prostate cancer?

Yes, in the preclinical literature. Two studies in high-impact journals have specifically investigated Phellinus linteus in prostate cancer: Zhu et al. (2007) in the British Journal of Cancer, studying apoptosis in two prostate cancer cell lines, and Tsuji et al. (2010) in PLoS ONE, studying tumor growth in a mouse xenograft model. Both found anti-tumor activity. A broader 2010 review by Sliva named prostate cancer among the cancer types with the most published PL anti-tumor evidence. No human prostate cancer trials have been published.

How does androgen receptor status affect Meshima's effect on prostate cancer?

Androgen receptor (AR) status determines which apoptotic pathway Phellinus linteus activates in prostate cancer cells. In AR-positive (hormone-driven) cells, PL activates caspase-8/BID and endoplasmic reticulum stress pathways together, producing a stronger dual-signal apoptotic response. In AR-negative (castration-resistant) cells, PL activates primarily a caspase-2 pathway that operates downstream of the androgen receptor, producing a more limited apoptotic response. The clinical implication is that hormone-sensitive prostate cancers may be more responsive to PL's principal apoptosis mechanism than castration-resistant prostate cancers, based on this single cell culture study.

Can Meshima sensitize prostate cancer to chemotherapy?

One animal study suggests it may. Tsuji et al. (2010) found that Phellinus linteus combined with doxorubicin produced greater prostate cancer cell death than doxorubicin alone in their mouse model. The mechanism appears to involve PL's ability to sensitize cancer cells to apoptotic death signals, lowering the threshold for caspase activation that doxorubicin requires. This finding is from a single mouse study and has not been tested in human prostate cancer patients. Drug interactions in human cancer treatment are complex; this preclinical sensitization signal cannot be directly applied to treatment decisions.

Sources & References

1. 1RTHM-00240·Zhu, T et al. (2007). “Phellinus linteus activates different pathways to induce apoptosis in prostate cancer cells..” British journal of cancer.Study breakdown →PubMed →↩
2. 2RTHM-00367·Tsuji, Takanori et al. (2010). “Phellinus linteus extract sensitizes advanced prostate cancer cells to apoptosis in athymic nude mice..” PloS one.Study breakdown →PubMed →↩
3. 3RTHM-00306·Lu, Te-Ling et al. (2009). “Hispolon from Phellinus linteus has antiproliferative effects via MDM2-recruited ERK1/2 activity in breast and bladder cancer cells..” Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.Study breakdown →PubMed →↩
4. 4RTHM-00792·Kim, Ji-Hun et al. (2016). “Hispolon from Phellinus linteus induces apoptosis and sensitizes human cancer cells to the tumor necrosis factor-related apoptosis-inducing ligand through upregulation of death receptors..” Oncology reports.Study breakdown →PubMed →↩
5. 5RTHM-00364·Sliva, Daniel (2010). “Medicinal mushroom Phellinus linteus as an alternative cancer therapy..” Experimental and therapeutic medicine.Study breakdown →PubMed →↩